These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000137-11 Open, randomized, controlled, multicenter phase III study comparing 5-FU/FA plus irinotecan plus cetuximab versus 5-FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-e... 2011-03-24 due-trials
Reported results 2004-000335-28 A phase IIIB/IV, open label study to assess the efficacy and safety of a pre-defined, fixed dose of Gonal-f Filled-by-Mass in a Prefilled Pen based on subject baseline characteristics, for ovarian s... 2006-03-20 due-trials
Reported results 2004-000337-12 A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects wi... 2006-01-31 due-trials
Reported results 2004-000530-37 A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered onercept in the initial treatment and continued treatment after extended therapy in subjects ... 2005-04-05 due-trials
Reported results 2004-000535-29 A multicentre, open label and subsequent randomised, double blind, placebo controlled phase III study to assess the safethy and efficacy of maintenance and extended therapy with subcutaneously adminis... 2005-06-01 due-trials
Completed, but no date, and reported results 2004-000649-39 A randomized, controlled, multicenter, phase I/II study of cetuximab plus irinotecan investigating the pharmacodynamics, genomics and -genetics as well as the safety and efficacy of a dose escalation... bad-data
Reported results 2004-001105-96 ''Open, randomized, controlled, multicenter phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with EGFR-expressing advanc... 2012-04-19 due-trials
Reported results 2004-001236-23 A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond ... 2007-04-30 due-trials
Reported results 2004-001503-36 Lutropin alfa (Luveris) in mid follicular phase for controlled ovarian stimulation (COS) in ovarian ageing: a randomised, comparative with parallel control group, phase II clinical trial. 2006-11-15 due-trials
Reported results 2004-001593-10 A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from trea... 2006-02-10 due-trials
Reported results 2004-001594-25 A double-blind, placebo controlled, multicenter, multinational, phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d in patients with Parkinson' s disease suffering from tre... 2006-03-22 due-trials
Reported results 2004-001667-22 Cetuximab (ERBITUX) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and nec... 2011-01-05 due-trials
Completed, but no date, and reported results 2004-002218-13 A phase III, multicenter, randomized, open, comparative study to evaluate if the addition of r-hLH (Luveris) ti FSH from day 8 of ovarian stimulation is able to decrease total FSH dose and to improve ... bad-data
Reported results 2004-002837-37 An exploratory pharmacogenomic study of cetuximab monotherapy in patients with metastatic EGFR-Positive colorectal carcinoma 2006-02-14 due-trials
Reported results 2004-003799-13 A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. 2007-06-29 due-trials
Reported results 2004-004849-18 Cilengitide (EMD121974) and temozolomide with concomitant radiation therapy, followed by cilengitide and temozolomide maintenance therapy in subjects with newly diagnosed glioblastoma multiforme – a m... 2012-01-31 due-trials
Reported results 2004-005054-31 A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome pre-pubertal children treated with SAIZEN. 2007-09-17 due-trials
Reported results 2004-005148-28 A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis 2008-12-19 due-trials
Reported results 2005-000146-36 Randomized Phase II open-label controlled study of EMD 72000 (matuzumab) in combination with the chemotherapy regimen ECX or the chemotherapy regimen ECX alone as first-line treatment in subjects with... 2008-08-06 due-trials
Reported results 2005-000444-84 An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson s disease suffering from tr... 2006-10-23 due-trials
Reported results 2005-000970-37 Open, randomized, controlled, multicenter phase II study comparing 5-FU/FA plus oxaliplatin FOLFOX-4 plus cetuximab versus 5-FU/FA plus oxaliplatin as first-line treatment for epidermal growth facto... 2010-09-09 due-trials
Reported results 2005-001026-89 Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple scleros... 2010-01-26 due-trials
Reported results 2005-001362-14 Open-label, single-arm, multicenter phase II study of matuzumab in combination with irinotecan background chemotherapy in subjects with epidermal growth factor receptor (EGFR)-expressing metastatic co... 2007-10-30 due-trials
Reported results 2005-002229-30 Lutropin alfa in mid follicular phase in women at risk of poor response suppresed with cetrorelix: an exploratory trial.Lutropina alfa en mitad de la fase folicular en mujeres con riesgo de pobre resp... 2007-01-30 due-trials
Completed, but no date, and reported results 2005-003144-65 Doubleblind, randomized, placebo controlled clinical trial to proof the efficacy of a comfrey extract in subjects with painfull gonarthrosis bad-data
Reported results Terminated 2005-004289-18 A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 4... 2011-04-07 due-trials
Reported results 2006-000579-14 START – Stimulating Targeted Antigenic Responses To NSCLC. A multi-center phase III randomized, double-blind placebo-controlled study of the cancer vaccine Stimuvax(L-BLP25 or BLP25 liposome vaccine... 2015-09-09 due-trials
Reported results 2006-000685-36 A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX-4 plus cetuximab versus UFOX plus cetuximab as first-line therapy in subjects with metastatic colorectal cancer 2012-05-15 due-trials
Exempt, with results 2006-000871-13 A Phase I/II, Open Label, Dose-Escalating Study Evaluating the Safety and Efficacy of the Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody EMD 72000 (Matuzumab) in Combination with the... 2006-10-30 not-yet-due
Reported results 2006-000899-32 Randomized, phase II, open-label controlled study of two different doses and schedules of EMD 72000 (matuzumab) in combination with pemetrexed, or pemetrexed alone, as second-line treatment in subject... 2009-06-05 due-trials
Reported results 2006-001810-33 A Phase II study with Stimuvax® (L-BLP25 liposome vaccine) in subjects with either chemotherapy-naive, slowly progressive asymptomatic multiple myeloma or with stage II/ III multiple myeloma following... 2012-05-07 due-trials
Reported results 2006-002902-74 A double-blind, double-dummy, randomized, controlled, multi-centre study of the activity and safety of 2 daily doses of EMD 387008 versus placebo and metformin in parallel groups after 8 weeks of trea... 2007-03-23 due-trials
Reported results 2006-002982-38 A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation 44 mcg tiw and 44 mcg ow in subjects at high risk of converting to Multiple Sclerosis 2011-09-16 due-trials
Reported results 2006-003037-32 A TWO-ARM, RANDOMISED, DOUBLE-BLIND, CONTROL GROUP-COMPARED, MULTICENTRE, PHASE IIIB STUDY WITH MONTHLY MRI AND BIOMARKER ASSESSMENT TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF REBIF NEW FOR... 2009-02-03 due-trials
Reported results Terminated 2006-003366-33 A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris Subj... 2012-03-29 due-trials
Reported results 2006-003621-87 Double-blind, placebo-controlled, randomised, parallel-groups, multi-centre clinical trial for the evaluation of efficacy and safety of an ointment of comfrey extract in comparison to placebo in the t... 2008-03-17 due-trials
Reported results 2006-004140-23 A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagon... 2009-09-29 due-trials
Reported results 2006-004516-51 A multicentre open-label, dose-escalation, trial of zanolimumab in combination with CHOP chemotherapy in subjects with CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement 2008-12-02 due-trials
Reported results 2006-004547-35 Phase IV study to investigate neutrophil downregulation of Thy-1 by Raptiva® (Efalizumab) as a potential responder predictor in patients with moderate to severe plaque psoriasis 2008-07-25 due-trials
Reported results 2006-004566-13 An open-label, randomised, phase II study in subjects with extensive disease, small cell lung cancer (ED-SCLC) after an initial response (complete response or partial response) to platinum-based thera... 2010-12-31 due-trials
Reported results 2006-005000-13 Randomized Phase II trial with cetuximab and cisplatin in the treatment of ER negative, PgR negative, HER2 negative metastatic breast carcinoma (“basal-like”) 2011-02-08 due-trials
Exempt 2006-005006-31 A randomized, stratified on age, parallel group design study to investigate the safety, tolerability and pharmacokinetics after a 60 minutes application of 4% lidocaine cream compared to EMLA® cream f... not-yet-due
Reported results 2006-005948-90 Tratamiento con hormona de crecimiento del síndrome de fibromialgia grave asociado a fallo funcional del eje somatotropo. Estudio multicéntrico, aleatorizado, doble ciego y controlado frente a placebo... 2010-07-31 due-trials
Reported results 2006-005972-42 A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interf... 2008-05-23 due-trials
Reported results 2007-000381-20 A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sc... 2012-02-16 due-trials
Reported results 2007-001377-28 Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of th... 2009-07-31 due-trials
Reported results 2007-002536-29 A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED MULTICENTRE PHASE II STUDY OF ATACICEPT IN ANTI-TNFA NAIVE PATIENTS WITH MODERATE TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO MET... 2009-10-30 due-trials
Reported results 2007-002823-34 A phase II, multicentre, randomised, assessor-blinded, active-comparator, parallel-group dose finding trial to evaluate AS900672-Enriched versus follitropin alfa (GONAL-f)in oligo-anovulatory infertil... 2009-05-19 due-trials
Reported results 2007-002963-28 A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with ... 2012-03-06 due-trials
Reported results 2007-002964-90 A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic P... 2012-03-29 due-trials
Reported results 2007-003647-75 A randomised, double-blind, placebo controlled, multi-centre, exploratory, pilot, phase II trial of 150 mg atacicept given subcutaneously in combination with rituximab in subjects with rheumatoid arth... 2011-05-19 due-trials
Reported results 2007-003698-13 A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic ... 2012-10-31 due-trials
Reported results 2007-003925-26 A two-arm, randomised, double-blind, placebo-controlled, multicenter phase II study to evaluate safety and tolerability and to explore the neuroprotective effect of atacicept as assessed by Optical Co... 2011-06-24 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-003936-50 A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept m... 2011-05-30 bad-data
Reported results 2007-003938-41 Open label pilot study on gene expression profiling of the endometrial tissue in patients undergoing Assisted Reproductive Technology (ART: only IVF) with GONAL-f. 2010-08-30 due-trials
Reported results 2007-004219-75 Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subj... 2013-02-17 due-trials
Reported results 2007-004227-37 "Ensayo clínico en fase IV, multicéntrico, aleatorizado, doble ciego y controlado frente a placebo, para evaluar la seguridad y la eficacia de Raptiva® en el tratamiento de pacientes con psoriasis en ... 2009-03-03 due-trials
Completed, but no date, and reported results Terminated 2007-004243-29 A Phase IV open label study in moderate to severe chronic plaque psoriasis subjects transitioning from previous systemic antipsoriasis therapies (methotrexate, cyclosporine, retinoids or PUVA, NBUVB) ... bad-data
Reported results 2007-004344-78 Cilengitida en pacientes con gioblastoma multiforme recién diagnosticado y con promotor metilado del gen MGMT-estudio multicéntrico, abierto y controlado en fase III para evaluar cilengitida en combin... 2013-07-30 due-trials
Reported results Terminated 2007-004518-15 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects with Lupus Nephritis in Combination with Mycophenolate Mofetil Therapy 2008-10-06 due-trials
Reported results Terminated 2007-005452-16 A multicentre randomised placebo-controlled, double-blind clinical trial for eval¬ua¬tion of safety and efficacy of pre-seasonal specific immunotherapy with a hypoallergenic extract of a 6 grass and r... 2009-11-23 due-trials
Reported results 2007-007932-25 A phase IIIb randomized open-label study to compare between IVF/ICSI outcomes two regimen of Cetrotide 0.25 mg used from Day 1 or from Day 7 of the menstrual cycle (Day 0 or Day 6 of stimulation) in ... 2012-02-28 due-trials
Reported results 2008-000499-25 International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmart suitability for selfinjection of Rebif New Formulation (RNF) in multidose cartridges in patients w... 2009-02-20 due-trials
Reported results 2008-000615-15 Open-label, randomized, controlled Phase I/II study of cilengitide to evaluate the safety and efficacy of the combination of different regimens of cilengitide added to cisplatin, 5-FU, and cetuximab i... 2013-07-29 due-trials
Reported results 2008-001174-33 A mulitnational, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of various ovarian responses to GONAL-f® tre... 2009-04-15 due-trials
Reported results 2008-001259-22 ?Ensayo clínico fase IV, prospectivo, multicéntrico, aleatorizado y abierto para evaluar la eficacia y seguridad de GONAL-f® a una dosis basada en las características iniciales de la paciente determi... 2010-04-26 due-trials
Reported results 2008-001966-10 A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinso... 2011-07-18 due-trials
Reported results 2008-002221-36 A Phase II/III, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of atacicept in combination with corticosteroids and sequential therapy with cyclophosphamide and... 2008-11-20 due-trials
Completed, but no date, and reported results 2008-002281-55 Estudio exploratorio para determinar el efecto de lutropina alfa en la calidad de los embriones y su implantación en mujeres de edad reproductiva avanzada bad-data
Reported results 2008-002354-38 A Phase IV, prospective, open label multicentre study of Raptiva 1mg/kg/week by subcutaneous injection in adults with moderate to severe chronic plaque psoriasis who have failed previous biologic ther... 2009-11-04 due-trials
Completed, but no date, and reported results 2008-002769-30 A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson�s diseas... bad-data
Reported results 2008-003706-33 A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS 2012-04-30 due-trials
Reported results 2008-004146-88 A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects w... 2012-06-18 due-trials
Reported results 2008-004148-35 Cilengitide and cetuximab in combination with platinum-based chemotherapy as first-line treatment for subjects with advanced NSCLC Open-label, randomized, controlled, multicenter Phase II study invest... 2013-07-29 due-trials
Reported results 2008-004454-33 OPEN RANDOMIZED MULTINATIONALPHASE IIIB TRIAL EVALUATING THE ACTIVITY AND SAFETY OF CETUXIMAB AS 250MG/M2 WEEKLY AND 500 MG/M2 EVERY TWO WEEKS MAINTENANCE THERAPY AFTER PLATINUM-BASED CHEMOTEHRAPY IN ... 2013-06-24 due-trials
Reported results 2008-004457-15 Cilengitide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter - a multicenter, open-label Phase II study, investigating two cilengitide regimens in combinati... 2013-08-01 due-trials
Reported results 2008-004954-34 Double-Blind Extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting t... 2013-09-30 due-trials
Reported results 2008-005021-11 An open-label, multicenter phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in patients with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS-Ex... 2011-02-28 due-trials
Reported results 2008-005492-94 OPEN LABEL TRIAL TO DETERMINE THE LONG TERM SAFETY OF SAFINAMIDE IN PARKINSON`S DISEASE PATIENTS 2012-07-13 due-trials
Reported results 2008-005544-17 A randomized, double-blind, controlled phase III study of Stimuvax (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy of ... 2010-09-10 due-trials
Reported results 2008-008721-29 Double-blind, randomised, multi-centre, placebo-controlled clinical trail to investigate the efficacy and safety of a combination of comfrey root extract plus methyl nicotinate versus a preparation co... 2011-05-04 due-trials
Reported results 2009-010866-49 Phase II Trial with Safety Run-in of MEK Inhibitor AS703026 in Subjects with Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies 2012-12-01 due-trials
Reported results 2009-011992-61 Ensayo de fase II, aleatorizado, del inhibidor de MEK AS703026 o placebo en combinación con gemcitabina, en pacientes con cáncer de páncreas metastásico no tratados previamente con quimioterapia. 2015-02-19 due-trials
Exempt, with results 2009-012040-16 An open-label, randomized, controlled, multi-center, Phase I/II trial investigating 2 EMD 525797 doses in combination with cetuximab + irinotecan versus cetuximab + irinotecan alone, as second-line tr... 2015-04-23 not-yet-due
Ongoing, reported early 2009-012208-18 ETUDE RANDOMISEE EN DEUX GROUPES PARALLELES DE L’EFFICACITE ET DE LA TOLERANCE DE L’ASSOCIATION D'AMYCOR-ONYCHOSET®, D'AMYCOR® CREME ET DE LA TERBINAFINE VERSUS L ADMINISTRATION DE TERBINAFINE SEULE ... not-yet-due
Completed, but no date Terminated 2009-012978-12 A Phase IV, prospective, open-label, uncontrolled, single-centre cohort trial to be conducted in Norway to assess the responsiveness of subjects with phenylketonuria (PKU) to treatment with Kuvan® 20 ... bad-data
Completed, but no date, and reported results 2009-013333-24 Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inject ... bad-data
Completed, but no date, and reported results 2009-013695-46 ETUDE MULTICENTRIQUE, RANDOMISEE EN DOUBLE AVEUGLE VERSUS PLACEBO EVALUANT L’EFFICACITE D’UN TRAITEMENT ADDITIONNEL PAR CHOLECALCIFEROL (VITAMINE D3) CHEZ DES PATIENTS ATTEINTS DE SCLEROSE EN PLAQUES ... bad-data
Reported results 2009-014440-10 A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination with Cetuximab in Second-Line Cetuximab-Naïve Subjects with Recurrent or Metastatic Squamo... 2013-07-23 due-trials
Reported results 2009-015502-19 A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multi... 2011-03-31 due-trials
Reported results 2009-015532-14 A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II trial to investigate the efficacy and safety of weekly intra-articular (i.a.) injections of 10, 30, and 100 µg of A... 2013-05-21 due-trials
Reported results 2009-015621-36 A double-blind, randomized, comparative, multicenter, exploratory, and placebo-controlled Phase II trial of FOLFIRI plus MSC1936369B or placebo with a safety run-in part as second-line treatment of... 2012-05-25 due-trials
Reported results 2009-015768-33 A Phase IIIb, Multicenter, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan) in Phenylketonuria (PKU) Patients <4... 2017-02-17 due-trials
Reported results 2009-015844-41 A Phase IV Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children with Phenylketonuria Treated with Sapropterin Dihydrochloride (Kuvan®) for 7 Years. 2023-01-04 due-trials
Reported results 2009-016087-37 A multinational, multicenter, single blood sampling exploratory pharmacogenetic study of the REGARD (the REbif vs Glatiramer Acetate in Relapsing MS Disease) trial 2011-01-26 due-trials
Reported results 2009-017174-20 A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering fr... 2012-01-12 due-trials
Reported results 2009-017978-21 Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE). Registro prospettico osservazionale sulla sicurez... 2019-11-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-018168-81 ENDURE: A Phase IV, prospective, open-label, uncontrolled, multi-centre cohort trial to assess the responsiveness of subjects with phenylketonuria (PKU) to treatment with Kuvan® 20 mg/kg/day for 28 da... 2012-05-02 bad-data
Reported results 2010-018705-11 A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS 2015-01-30 due-trials
Reported results 2010-020109-34 A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson... 2012-04-05 due-trials
Reported results 2010-020196-23 A phase II, multicentre, open label, prospective, interventional study to evaluate the sperm DNA fragmentation in idiopathic male infertility before and after treatment with Gonal-f PEN 900 IU. 2013-02-28 due-trials
Reported results 2010-020328-23 A THREE-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER, PHASE II STUDY TO EVALUATE THE EFFICACY OF VIGANTOL OIL AS ADD-ON THERAPY IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSI... 2015-05-25 due-trials
Reported results 2010-021529-11 A randomized, double-blind, placebo-controlled, multicenter Phase II trial investigating two doses of EMD 525797 in subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prost... 2014-07-08 due-trials
Reported results 2010-023430-23 A phase IIIb, open-label, single-arm, multicenter study to assess the immunogenicity of the r-hGH liquid multidose formulation (Saizen solution for injection) when administered to male and female adul... 2011-12-19 due-trials
Reported results 2010-023534-23 A phase IIIB, multicentre, multinational, randomized, open-label trial to compare the efficacy and safety of ovarian stimulation with GONAL-f day 1 to day 5 followed by Pergoveris starting day 6 to P... 2012-09-26 due-trials
Completed, but no date, and reported results 2010-024311-13 A Multicenter, Double-Blind, Placebo Controlled, Randomized, 2-Arm Phase IIa Pilot Trial Assessing the Effect of Sapropterin on Cognitive Abilities in Young Adults with Phenylketonuria bad-data
Reported results 2011-000460-10 First year growth response associated genetic markers validation Phase IV open-label study in Growth Hormone Deficient and Turner Syndrome pre-pubertal children : the PREDICT Pharmacogenetics Validati... 2012-10-03 due-trials
Reported results 2011-000847-25 A multi-center, randomized, open-label, mechanism of action trial on the biological effects of the therapeutic cancer vaccine Stimuvax® (L-BLP25) in rectal cancer subjects undergoing neoadjuvant chemo... 2014-06-12 due-trials
Reported results 2011-003059-20 A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of different intra-articular (i.a.) dosages of sprifermin in subjects with prim... 2019-05-07 due-trials
Reported results 2012-001431-31 A multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II trial to investigate the efficacy and safety of 30 mcg and 100 mcg AS902330 given as one cycle of three intra-arti... 2013-09-10 due-trials
Reported results 2012-002669-37 A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutane... 2016-10-24 due-trials
Reported results 2012-002957-42 A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects ... 2016-05-04 due-trials
Exempt, with results 2012-003126-25 An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors 2020-03-11 not-yet-due
Reported results 2012-003227-38 A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects with Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing Ovu... 2015-07-23 due-trials
Reported results 2012-004263-47 Open-label, single-arm, phase IV, multicenter trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD) 2016-03-21 due-trials
Reported results 2013-000902-40 Phase II Randomized Double Blind Placebo controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated Unresectable Low Grade... 2017-12-08 due-trials
Exempt, with results 2013-002053-30 A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liver Fu... 2018-02-14 not-yet-due
Reported results 2013-002283-25 A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study To Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone... 2015-03-03 due-trials
Reported results Terminated 2013-002351-15 A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-?-1a 30 µg IM Weekly i... 2014-09-02 due-trials
Reported results 2013-002758-62 A Phase IIb, Multi-Center, Long-Term Extension Trial to Evaluate the Safety and Tolerability of Atacicept in Subjects with Systemic Lupus Erythematosus (SLE) who Completed Protocol EMR-700461-023 (ADD... 2018-07-16 due-trials
Reported results 2013-002773-21 A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE) 2016-12-08 due-trials
Reported results 2013-002916-28 An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis 2016-04-11 due-trials
Listed as ongoing, but also has a completion date 2013-003126-83 A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-?-1a 30 µg IM Weekly i... 2014-08-28 bad-data
Reported results 2013-003760-30 A multicenter, randomized, double-blind, placebo-controlled phase III trial of tecemotide versus placebo in subjects with completed concurrent chemo-radiotherapy for unresectable stage III non-small c... 2015-07-02 due-trials
Reported results 2013-003817-16 A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris® (follitropin alfa and lutropin alfa) and GONAL-f® (follitropin alfa)... 2015-08-05 due-trials
Reported results 2013-003829-29 Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects with Metastatic Colorect... 2017-04-26 due-trials
Reported results 2013-004450-21 Multicenter, open-label, 12 weeks, phaseIV pRospectivE randomized study aimed at evaLuating whether sc IFN beta 1a (Rebif®) administered In the morning may affEct the severity of Flu-like syndrome and... 2017-05-11 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-000445-79 A Phase II, open-label, multicenter trial to investigate the clinical activity and safety of MSB0010718C in subjects with Merkel cell carcinoma 2023-04-04 bad-data
Reported results 2014-001290-14 Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania using Electronic Device RebiSmart™ Studiu clinic prospectiv faza IV privind eficacitatea t... 2016-08-06 due-trials
Reported results 2014-005060-15 A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet 2019-12-16 due-trials
Listed as ongoing, but also has a completion date 2015-001537-24 A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum based doublet as a first line treatment of recurrent or Stage IV PD L1+ non small cell lung cancer 2024-01-29 bad-data
Trial is outside EEC, and reported results 2015-001569-20 A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen® bad-data
Trial is outside EEC, and reported results 2015-001650-15 A Phase III Non-comparative Open-label Clinical Study to Evaluate the Response to and Safety of Kuvan (Sapropterin Dihydrochloride) After 6 Weeks of Treatment in Patients of 4 to 18 Years of Age With ... bad-data
Trial is outside EEC, and reported results 2015-001681-25 An Open, Multicenter, Randomized, Controlled Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expre... bad-data
Trial is outside EEC, and reported results 2015-001696-51 Optimization of the Dosage Regimen With Growth Hormone Therapy in Children Born Small for Gestational Age. An Open Label, Randomized, Pilot Study, Comparing in Children Treated for 3 Years, the Effica... bad-data
Trial is outside EEC, and reported results 2015-001708-69 An Open Study of the Safety and Efficacy of Saizen®, (Recombinant Human Growth Hormone, r-hGH), in Children Born With Serious Intra-uterine Growth Retardation (IUGR) Treated to Final Height bad-data
Reported results 2015-003287-37 A randomized, double-blind, confirmatory trial to evaluate the efficacy, safety and immunogenicity of MSB11022 compared with European Union-Approved Humira® in subjects with moderate to severe chronic... 2017-12-18 due-trials
Listed as ongoing, but also has a completion date and reported results 2015-003300-23 A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastat... 2021-06-03 bad-data
Reported results 2015-003301-42 A Phase III open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma 2019-11-14 due-trials
Reported results Terminated 2015-005023-11 A Phase II, randomized, double-blind, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitia... 2018-05-31 due-trials
Ongoing 2015-005696-24 A Phase II single-arm trial to investigate tepotinib in advanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISIO... not-yet-due
Reported results 2016-000064-42 Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects with Rheumatoid Arthritis on Stable Methotrexate Therapy 2017-11-24 due-trials
Listed as ongoing, but also has a completion date 2016-001448-21 A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 with a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients with Relapsing Multiple Sclerosis to Evaluate Efficacy... 2024-04-02 bad-data
Exempt, with results 2016-001604-28 A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib(MSC2156119J) Combined with Gefitinib Versus Chemotherapy as Second-line Treatment in Subjects with MET Positive, Locally Ad... 2021-08-12 not-yet-due
Reported results 2016-002262-31 A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy 2020-02-07 due-trials
Reported results 2016-002852-26 A multicenter, randomized, double-blind, Phase III trial to evaluate the safety, immunogenicity, and efficacy of MSB11022 compared with Humira® in patients with moderately to severely active rheumatoi... 2018-08-29 due-trials
Reported results 2016-002950-19 A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE) 2020-07-22 due-trials
Reported results 2017-000384-32 A Phase IIb, Randomized, Double blind Study in Subjects with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Subjects with an Inadequate Response to Met... 2019-09-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-002631-42 A 2-year prospective study to evaluate the onset of action of Mavenclad® in subjects with highly active relapsing multiple sclerosis 2021-10-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2017-002632-17 A 2-year Prospective Study to Assess Health-related Quality of Life in Subjects with Highly-Active Relapsing Multiple Sclerosis Treated with Mavenclad® 2021-08-26 bad-data
Reported results 2017-002985-28 Open-label, Phase I/II study to evaluate pharmacokinetics, pharmacodynamics, safety, and anticancer activity of avelumab in pediatric subjects from birth to less than 18 years of age with refractory o... 2021-05-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-001517-32 A Phase II, Multicenter, Randomized, Open- Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer 2024-06-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2018-001529-24 A Phase IIa, single-arm, multi center study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with advanced squam... 2021-05-27 bad-data
Reported results 2018-001534-17 A Phase II, Randomized, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination with Avelumab and Carboplatin in Comparison to Standard of Care Th... 2019-11-06 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-002275-18 A multicenter study with an open-label Phase Ib part followed by a randomized, placebo-controlled, double-blind, Phase II part to evaluate efficacy, safety, tolerability, and pharmacokinetics of the D... 2021-04-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2018-003265-34 A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants... 2023-02-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2018-003707-19 A Phase II, Multicenter, Open label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant ... 2022-10-19 bad-data
Ongoing 2018-003711-21 An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies not-yet-due
Exempt, with results 2018-004040-28 A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non-small Cell Lung Cancer 2022-06-13 not-yet-due
Reported results Terminated 2018-004700-19 A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with an Interferon Beta 1a (Avonex®), in Participants with Relapsing M... 2020-02-18 due-trials
Reported results Terminated 2018-004701-11 A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with an Interferon Beta 1a (Avonex®), in Participants with Relapsing M... 2020-02-18 due-trials
Reported results 2019-000069-19 Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Par... 2022-01-27 due-trials
Other 2019-001538-33 A Phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and havin... not-yet-due
Reported results 2019-001992-35 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp alfa (M7824) as First-line Treatment of Biliary Tract Cancer 2022-11-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2019-003583-40 A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Containin... 2023-01-03 bad-data
Reported results 2019-004833-18 A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with HMGA2-expressing Triple Negative Breast Cancer 2022-04-21 due-trials
Listed as ongoing, but also has a completion date 2019-004972-20 A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis ... 2024-03-08 bad-data
Listed as ongoing, but also has a completion date 2019-004980-36 A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis ... 2024-03-19 bad-data
Completed, report not yet due 2020-000377-25 A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with ... 2024-09-18 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2020-001776-15 A Phase II single-arm study to investigate tepotinib combined with cetuximab in RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) patients having acquired resistance to anti-EGFR antib... 2022-01-19 bad-data
Reported results 2020-003874-30 A 2-year follow-up study to assess cognition and health-related quality of life in participants with highly-active relapsing multiple sclerosis, having participated in the CLARIFY MS trial 2023-06-20 due-trials
Reported results 2020-003995-42 A 2-year extension study to evaluate long-term effectiveness of Mavenclad® in participants who have completed Trial MS700568_0022 (MAGNIFY MS) 2023-09-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2020-004231-25 A Phase II, open-label, single-arm study of berzosertib (M6620) in combination with topotecan in participants with relapsed platinum-resistant small-cell lung cancer 2022-09-19 bad-data
Other 2020-004397-22 Single-arm, multicenter Phase I/Ib study of avelumab + lenvatinib in children with primary CNS tumors not-yet-due
Ongoing 2021-000179-36 An Open-label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Bintrafusp alfa (M7824) Clinical Studies not-yet-due
Ongoing 2021-003669-36 A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Loca... not-yet-due
Other 2021-004648-27 A Phase 2, Randomized, Double-Blind, Placebo Controlled Dose-Ranging, Parallel and Adaptive Study to evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupu... not-yet-due
Other 2022-000239-21 A Phase 2, Double-blind, Dose-Ranging, Parallel, Long-term Extension Study to Evaluate the Safety and Efficacy of Enpatoran in Participants with Subacute Cutaneous Lupus Erythematosus, Discoid Lupus E... not-yet-due
Other 2022-001144-18 A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of... not-yet-due